Breaking Finance News

SunTrust downgraded Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral in a report released today.

SunTrust has downgraded Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral in a statement released on Thursday September 29, 2016.

On 6/2/2016, Piper Jaffray released a statement on Intra-Cellular Therapies (NASDAQ:ITCI) upped the target price from $0.00 to $57.00 that suggested an upside of 0.42%.

Having a price of $42.35, Intra-Cellular Therapies (NASDAQ:ITCI) traded 2.00% higher on the day. With the last close up 13.23% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Intra-Cellular Therapies has recorded a 50-day average of $41.71 and a two hundred day average of $37.40. Volume of trade was up over the average, with 3,016,643 shares of ITCI changing hands over the typical 407,919

Performance Chart

Intra-Cellular Therapies (NASDAQ:ITCI)

With a total market value of $0, Intra-Cellular Therapies has with a one year low of $22.41 and a one year high of $59.96 .

A total of 8 analysts have released a report on Intra-Cellular Therapies. Three analysts rating the company a strong buy, four analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $74.25.

More About Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company's pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.